Margaret Collins belongs to a community of researchers at Cincinnati Children’s Hospital Medical Center, plus other institutions in the USA and abroad, who are unwaveringly committed to finding cures for pediatric gastrointestinal (GI) diseases, including eosinophilic gastrointestinal disorders (EGID). This is especially important to her after meeting patients and their caregivers, witnessing the impact that EGID has on their lives, and sharing their hope for a Food and Drug Administration (FDA)-approved therapy.
Her research strives to improve diagnostic methods for children with GI diseases, such as EGID and inflammatory bowel disease. As a pediatric pathologist at Cincinnati Children’s, she helps evaluate the efficacy of various therapies, including biologics, for pediatric patients who have EGID. She also participates in multi-institutional studies of pediatric inflammatory bowel disease.
She helped create the eosinophilic esophagitis histology scoring system (EoEHSS), which systematically evaluates esophageal biopsies obtained for eosinophilic esophagitis, the most common form of EGID. Some of the features evaluated correlate with symptoms and potentially provide new therapeutic endpoints.
Beginning in 2011, U.S. News & World Report named me one of the Top Doctors in Pathology. In 2020, she received the American Academy of Asthma, Allergy, and Immunology (AAAAI) and American Partnership for Eosinophilic Disorders (APFED) award for the best EGID abstract at the AAAAI annual meeting.
